Sanofi-Aventis Inks $500M Deal For Cancer Therapy
Under the agreement, Sanofi-Aventis will pay Dyax Corp. up to $500 million in licensing fees and milestone payments, should the antibodies become commercially successful. Dyax will receive $25 million this year, and is eligible to receive royalties based on commercial sales of the technology.
Dyax keeps co-development and profit-sharing rights to the technology, while Sanofi-Aventis will...
To view the full article, register now.